$R

Ryder System, Inc. Stock 12‑Month Price Target Raised to $298.44, Implies 11% Upside

Analyst estimates for Ryder System, Inc. show the 12-month average price target increased from $294 to $298.44, with a range of $283 to $320, according to 9 analysts. Based on the Jul. 23 close, the target implies about 11% upside. The consensus rating remains “Buy” with 8 Buys, 4 Holds, and 1 Sell.

Original reporting
Published Jul 24, 2026, 5:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 24, 2026, 7:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ryder System, Inc. Stock 12‑Month Price Target Raised to $298.44, Implies 11% Upside — source image
Decision brief

The 30-second read

$RBullishLow
01

Why it matters

A higher consensus target and maintained “Buy” rating can influence short-term sentiment, but the text lacks any new Ryder-specific operational or financial datapoint.

02

Market read

Traders may treat this as mild bullish sentiment input rather than a standalone catalyst.

03

What to watch

The article provides no thesis behind the target change, no changes to estimates, and no mention of upcoming earnings or guidance that could validate the new target.

Relevance 4/10Novelty 4/10Timing: as of Jul. 23 close, with target update reported today

Background

The piece summarizes FactSet-sourced consensus analyst targets and ratings for Ryder System.

Company-level read

Ticker impact

$RBullishMedium confidence
Context

Ryder System’s average analyst price target rose from $294 to $298.44, implying about 11% upside versus the Jul. 23 close.

Expected impact

Likely modest near-term support from sentiment/positioning, with limited follow-through unless accompanied by new company guidance or results.

Evidence & confidence

The article only reports consensus price-target changes and implied upside; no earnings, guidance, or operational catalyst is disclosed.

Market effects

Minimal. Analyst target revisions for a single name typically do not reset sector fundamentals without accompanying macro or industry data.

Minimal, as the update is company-specific and not tied to a regional macro shock.

Low. No global supply chain, policy, or cross-border transaction is mentioned.

Counterpoint

Price-target increases can lag or reflect model recalibration rather than new information, so the stock may not follow if fundamentals do not improve.

Key entities

  • Ryder System, Inc.

    Subject of the article; consensus price target raised to $298.44 and implied upside cited.

Related articles

$RMed

Ryder System, Inc. Q2 2026 Earnings Call Summary

Ryder System reported 12% comparable EPS growth, citing execution and a shift toward less capital-intensive, asset-light revenue. Management raised full-year 2026 comparable EPS to $14.40 to $14.80, with $2.4B capex and $14.0B capital capacity over three years. It said 90%+ revenue is from long-term contracts and discussed supply chain and rental demand risks.

$RMedAI 8/10

Once again, Ryder’s bottom line is boosted by used vehicle sales

Ryder (NYSE:R) reported Q2 non-GAAP EPS of $3.73, up 12% year over year, and slightly raised 2026 guidance to $14.40-$14.80. Used vehicle sales supported results, with tractor and truck prices up 3% and 6% and gains on used sales expected around $40 million for 2026. Citi said results were broadly in line.

$RMed

RYDER SYSTEM INC (R): Results of Operations and Financial Condition

RYDER SYSTEM INC (R) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q26pressreleasedocument.htm EX-99.1 Document News Release Ryder Reports Second Quarter 2026 Results Strategic initiatives drive earnings growth; Transformed business model well positioned to benefit from cycle upturn Second Quarter 2026 Highlights • GAAP EPS from cont

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.